Value of CRP/PCT Ratio in Early Treatment of Community-Acquired Pneumonia Patients
OBJECTIVE:To evaluate the application value of C-reactive proten(CRP)/procalcitonin(PCT)ratio in the selection of antibiotics for community-acquired pneumonia patients.METHODS:In 2022,79 patients with community-acquired pneumonia treated with CRP/PCT ratio intervention medication were extracted as the intervention group,and 121 patients with community-acquired pneumonia treated in the hospital during the same period were selected as the control group.The clinical treatment effects of two groups were compared.RESULTS:After CRP/PCT ratio intervention medication,compared with the corresponding pathogen in the control group,the duration of length of stay in the intervention group with typical pathogen was shorter and the average cost per visit was lower(P<0.05);in the intervention group with atypical pathogen,the length of stay was significantly shortened,and the average cost per visit decreased significantly(P<0.01),with statistically significant differences.Compared with atypical pathogen pathogen in the control group,the application rate of β-lactam antibiotics and average cost per visit in atypical pathogen of the intervention group decreased significantly,and the effective rate of the initial antibiotic therapy was significantly improved,with statistically significant differences(P<0.01).There were no significant differences in the incidence of adverse drug reactions and 30 d recurrence between two groups(P>0.05).CONCLUSIONS:For patients with community-acquired pneumonia,the CRP/PCT ratio can be used as a quick basis for early selection of antibiotics.
Community-acquired pneumoniaTypical pathogenAtypical pathogenCRP/PCT ratio
万方数据
维普
